Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.36 |
| ▸ | ADORA1 | P30542 | 4/20 | 0.33 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.33 |
| ▸ | PDE7A | Q13946 | 2/20 | 0.31 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.30 |
| ▸ | PDE7B | Q9NP56 | 1/20 | 0.30 |
| ▸ | TERT | O14746 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20930963 | 0.86 | PDE7A (0.33) | ACE2ADORA1ADORA2APDE7AADORA3 | |
| SCHEMBL21913653 | 0.81 | LMNA (0.35) | ADORA1ADORA2APDE7AADORA3LMNA | |
| SCHEMBL6124132 | 0.81 | ADORA3 (0.31) | ACE2ADORA1ADORA2AADORA3LMNA | |
| SCHEMBL20782892 | 0.80 | SLC22A12 (0.42) | ACE2 | |
| SCHEMBL17208942 | 0.76 | ADORA1 (0.33) | ADORA1ADORA2AADORA3LMNA | |
| SCHEMBL8737563 | 0.76 | GPR55 (0.39) | LMNA | |
| SCHEMBL24498853 | 0.74 | NEK1 (0.33) | — | |
| SCHEMBL14602393 | 0.74 | — | — | |
| SCHEMBL14602394 | 0.70 | — | — | |
| SCHEMBL6127882 | 0.68 | GPR55 (0.35) | LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10597364-B2 | Anthelmintic compounds, compositions and method of using thereof | Boehringer Ingelheim Animal Health USA Inc. (US) | 2020-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10597364-B2 | Anthelmintic compounds, compositions and method of using thereof | CYP8B1, CYP2C8, CYP2B6 | ACE2 1228/4885ADORA1 804/4885ADORA2A 1916/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.